Alphamab Oncology (STU:3NK) EV-to-FCF : -28.93 (As of Apr. 04, 2025)

Alphamab Oncology EV-to-FCF Chart

Alphamab Oncology Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
EV-to-FCF	Get a 7-Day Free Trial										-18.80	-	-19.67	-	-

Competitive Comparison of Alphamab Oncology's EV-to-FCF

For the Biotechnology subindustry, Alphamab Oncology's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alphamab Oncology's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alphamab Oncology's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Alphamab Oncology's EV-to-FCF falls into.

Alphamab Oncology EV-to-FCF Calculation

Alphamab Oncology's EV-to-FCF for today is calculated as:

Alphamab Oncology's current Enterprise Value is €720.76 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Alphamab Oncology's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 was €-24.91 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alphamab Oncology  (STU:3NK) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Alphamab Oncology's PE Ratio (TTM) for today is calculated as:

Alphamab Oncology's share price for today is €0.91.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Alphamab Oncology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was €0.023.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.

Alphamab Oncology EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Alphamab Oncology's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.

Alphamab Oncology Business Description